Do analysts prefer LIAN or CABR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, LIAN or CABR?

Caring Brands is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Caring Brands N/A N/A -$6.28M -$0.74 N/A

Is LIAN or CABR more profitable?

LianBio's return on equity of -33.17% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Caring Brands N/A -1,153.12% -322.63%

Do analysts rate DARE or LIAN?

Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 1,582.79%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DARE or LIAN more profitable?

LianBio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. LianBio's return on equity of -33.17% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% LianBio N/A -33.17% -30.19%

Do analysts prefer LIAN or MBRX?

Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, LIAN or MBRX?

Moleculin Biotech is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is LIAN or MBRX more profitable?

LianBio's return on equity of -33.17% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Moleculin Biotech N/A -143.51% -24.53%

Which has higher earnings & valuation, LIAN or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is LIAN or FNCH more profitable?

LianBio's return on equity of -33.17% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts rate ASBP or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

LianBio (LIAN) Competitors

$0.04 0.00 (0.00%)

As of 09/2/2026

Compare

LIAN vs. CABR, DARE, MBRX, FNCH, and ASBP

Should you buy LianBio stock or one of its competitors? LianBio's main competitors and comparable companies include Caring Brands (CABR), Dare Bioscience (DARE), Moleculin Biotech (MBRX), Finch Therapeutics Group (FNCH), and Aspire Biopharma (ASBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LianBio compare to Caring Brands?

LianBio (NASDAQ:LIAN) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Caring Brands had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Caring Brands and 0 mentions for LianBio. Caring Brands' average media sentiment score of 0.83 beat LianBio's score of 0.00 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Caring Brands	Positive

Caring Brands is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 14.6% of Caring Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LianBio's return on equity of -33.17% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Caring Brands	N/A	-1,153.12%	-322.63%

Summary

Caring Brands beats LianBio on 6 of the 10 factors compared between the two stocks.

How does LianBio compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Dare Bioscience has higher revenue and earnings than LianBio. Dare Bioscience is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LianBio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. LianBio's return on equity of -33.17% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
LianBio	N/A	-33.17%	-30.19%

In the previous week, Dare Bioscience had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Dare Bioscience and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that LianBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
LianBio	Neutral

Dare Bioscience has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 1,582.79%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dare Bioscience beats LianBio on 8 of the 15 factors compared between the two stocks.

How does LianBio compare to Moleculin Biotech?

LianBio (NASDAQ:LIAN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Moleculin Biotech is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LianBio's return on equity of -33.17% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Moleculin Biotech	N/A	-143.51%	-24.53%

74.8% of LianBio shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 18.0% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Moleculin Biotech had 8 more articles in the media than LianBio. MarketBeat recorded 8 mentions for Moleculin Biotech and 0 mentions for LianBio. Moleculin Biotech's average media sentiment score of 0.11 beat LianBio's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Moleculin Biotech	Neutral

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Summary

Moleculin Biotech beats LianBio on 9 of the 13 factors compared between the two stocks.

How does LianBio compare to Finch Therapeutics Group?

LianBio (NASDAQ:LIAN) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

LianBio's return on equity of -33.17% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

In the previous week, LianBio's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Finch Therapeutics Group	Neutral

74.8% of LianBio shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

LianBio and Finch Therapeutics Group tied by winning 4 of the 8 factors compared between the two stocks.

How does LianBio compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LianBio has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
LianBio	N/A	-33.17%	-30.19%

In the previous week, Aspire Biopharma's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
Aspire Biopharma	Neutral
LianBio	Neutral

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aspire Biopharma has higher revenue and earnings than LianBio. Aspire Biopharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,295.00	-$24.48M	-$69.62	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

LianBio beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.32M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.05	787.27	273.29	25.25
Price / Sales	N/A	755.95	621.79	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.01	12.31	13.08	6.14
Net Income	-$110.29M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.59%	0.52%	-0.31%
1 Month Performance	N/A	6.95%	5.63%	0.64%
1 Year Performance	N/A	9.44%	25.31%	14.83%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.04 flat	N/A	-30.4%	$4.32M	N/A	N/A	110
CABR Caring Brands	0.4441 of 5 stars	$1.33 +3.5%	N/A	N/A	$13.32M	N/A	N/A	4	Gap Down
DARE Dare Bioscience	2.0779 of 5 stars	$0.75 -8.5%	$10.00 +1,232.3%	-65.4%	$12.55M	$1.03M	N/A	30
MBRX Moleculin Biotech	3.1703 of 5 stars	$0.60 -1.8%	$22.00 +3,566.7%	-92.8%	$11.90M	N/A	N/A	20	News Coverage Analyst Revision
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors

LIAN vs. CABR, DARE, MBRX, FNCH, and ASBP

How does LianBio compare to Caring Brands?

Summary

How does LianBio compare to Dare Bioscience?

Summary

How does LianBio compare to Moleculin Biotech?

Summary

How does LianBio compare to Finch Therapeutics Group?

Summary

How does LianBio compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LianBio (LIAN) Competitors

LIAN vs. CABR, DARE, MBRX, FNCH, and ASBP

How does LianBio compare to Caring Brands?

Does the media refer more to LIAN or CABR?

Which has preferable earnings & valuation, LIAN or CABR?

Do institutionals and insiders have more ownership in LIAN or CABR?

Do analysts prefer LIAN or CABR?

Is LIAN or CABR more profitable?

Summary

How does LianBio compare to Dare Bioscience?

Which has higher earnings and valuation, DARE or LIAN?

Do insiders and institutionals hold more shares of DARE or LIAN?

Is DARE or LIAN more profitable?

Does the media prefer DARE or LIAN?

Which has more risk & volatility, DARE or LIAN?

Do analysts rate DARE or LIAN?

Summary

How does LianBio compare to Moleculin Biotech?

Which has preferable valuation and earnings, LIAN or MBRX?

Do analysts prefer LIAN or MBRX?

Is LIAN or MBRX more profitable?

Do institutionals and insiders have more ownership in LIAN or MBRX?

Does the media prefer LIAN or MBRX?

Which has more risk & volatility, LIAN or MBRX?

Summary

How does LianBio compare to Finch Therapeutics Group?

Which has more volatility & risk, LIAN or FNCH?

Which has higher earnings & valuation, LIAN or FNCH?

Is LIAN or FNCH more profitable?

Does the media prefer LIAN or FNCH?

Do insiders & institutionals hold more shares of LIAN or FNCH?

Summary

How does LianBio compare to Aspire Biopharma?

Do analysts rate ASBP or LIAN?

Is ASBP or LIAN more profitable?

Does the media favor ASBP or LIAN?

Do institutionals and insiders believe in ASBP or LIAN?

Which has preferable valuation and earnings, ASBP or LIAN?

Which has more volatility & risk, ASBP or LIAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools